CY1109661T1 - 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης - Google Patents

5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης

Info

Publication number
CY1109661T1
CY1109661T1 CY20091101231T CY091101231T CY1109661T1 CY 1109661 T1 CY1109661 T1 CY 1109661T1 CY 20091101231 T CY20091101231 T CY 20091101231T CY 091101231 T CY091101231 T CY 091101231T CY 1109661 T1 CY1109661 T1 CY 1109661T1
Authority
CY
Cyprus
Prior art keywords
administration
cnac
agent
oral
parameters
Prior art date
Application number
CY20091101231T
Other languages
English (en)
Inventor
Moise Azria
Simon David Bateman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1109661T1 publication Critical patent/CY1109661T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Παρέχονται φαρμακευτικές συνθέσεις για τη δραστική χορήγηση από το στόμα της παραθορμόνης, PTH, καθώς και μέθοδοι για τη χορήγηση των συνθέσεων. Επιπλέον, παρέχονται επίσης μέθοδοι για τη διέγερση νέου σχηματισμού οστών και για τη θεραπευτική αντιμετώπιση και/ή την πρόληψη της οστεοπόρωσης.
CY20091101231T 2001-08-17 2009-11-25 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης CY1109661T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31304801P 2001-08-17 2001-08-17
EP02794796A EP1420827B8 (en) 2001-08-17 2002-08-16 5-cnac as oral delivery agent for parathyroid hormone fragments

Publications (1)

Publication Number Publication Date
CY1109661T1 true CY1109661T1 (el) 2014-08-13

Family

ID=23214149

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101231T CY1109661T1 (el) 2001-08-17 2009-11-25 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης

Country Status (26)

Country Link
US (4) US20040242478A1 (el)
EP (1) EP1420827B8 (el)
JP (2) JP4959917B2 (el)
KR (1) KR20040030120A (el)
CN (1) CN1279981C (el)
AT (1) ATE443527T1 (el)
AU (1) AU2002333443C1 (el)
BR (1) BRPI0211932B1 (el)
CA (1) CA2453646C (el)
CO (1) CO5560586A2 (el)
CY (1) CY1109661T1 (el)
DE (1) DE60233803D1 (el)
DK (1) DK1420827T3 (el)
EC (1) ECSP044961A (el)
ES (1) ES2333587T3 (el)
HU (1) HUP0401441A3 (el)
IL (2) IL159714A0 (el)
MX (1) MXPA04001418A (el)
NO (1) NO328069B1 (el)
NZ (1) NZ531018A (el)
PL (1) PL210258B1 (el)
PT (1) PT1420827E (el)
RU (1) RU2322256C2 (el)
SI (1) SI1420827T1 (el)
WO (1) WO2003015822A1 (el)
ZA (1) ZA200400242B (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60218842T2 (de) * 2001-06-01 2007-12-20 Novartis Ag Orale verabreichung von parathyroidhormon und calcitonin
JP4959917B2 (ja) * 2001-08-17 2012-06-27 ノバルティス アーゲー 副甲状腺ホルモンフラグメント用経口送達剤としての５−ｃｎａｃ
ATE381336T1 (de) * 2002-04-10 2008-01-15 Univ Virginia Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
US7749954B2 (en) 2003-07-23 2010-07-06 Novartis Ag Use of calcitonin in osteoarthritis
GB0427600D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
US8110547B2 (en) * 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
WO2006135915A2 (en) * 2005-06-13 2006-12-21 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
KR20080049128A (ko) 2005-09-19 2008-06-03 에미스페어 테크놀로지스, 인코포레이티드 Ｎ-(5-클로로살리실로일)-8-아미노카프릴산 이나트륨염의결정형
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
CA2628945A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
ES2426485T3 (es) * 2006-08-31 2013-10-23 Novartis Ag Composiciones farmacéuticas que comprenden hGH para administración oral
ES2365648T3 (es) 2007-03-02 2011-10-07 Novartis Ag Administración oral de una calcitonina.
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
AU2009356227A1 (en) 2009-12-07 2012-06-21 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
CN107427481A (zh) * 2015-02-09 2017-12-01 安特拉贝欧有限公司 骨质疏松症的治疗
KR101796604B1 (ko) * 2016-08-30 2017-11-10 목포대학교 산학협력단 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
WO1993011786A1 (en) * 1991-12-17 1993-06-24 Procter & Gamble Pharmaceuticals, Inc. Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone
ATE220327T1 (de) * 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ES2263428T3 (es) * 1997-02-07 2006-12-16 Emisphere Technologies, Inc. Compuesto y composicion para agentes activos de administracion.
AU1918300A (en) * 1998-11-25 2000-06-13 General Hospital Corporation, The Amino-terminal modified parathyroid hormone (pth) analogs
EP1175390B1 (en) * 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
WO2001070219A1 (en) * 2000-03-21 2001-09-27 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides via a dicarboxylate intermediate
DE60218842T2 (de) * 2001-06-01 2007-12-20 Novartis Ag Orale verabreichung von parathyroidhormon und calcitonin
JP4959917B2 (ja) * 2001-08-17 2012-06-27 ノバルティス アーゲー 副甲状腺ホルモンフラグメント用経口送達剤としての５−ｃｎａｃ
PL1651248T3 (pl) * 2003-07-11 2010-02-26 Novartis Ag Doustnie dawkowana kompozycja farmaceutyczna zawierająca środek dostarczający w postaci mikronizowanej

Also Published As

Publication number Publication date
PT1420827E (pt) 2009-12-15
US20090264367A1 (en) 2009-10-22
MXPA04001418A (es) 2004-05-27
AU2002333443C1 (en) 2009-10-08
CA2453646A1 (en) 2003-02-27
US20120088725A1 (en) 2012-04-12
NO20040598L (no) 2004-02-10
ZA200400242B (en) 2004-11-18
US20040242478A1 (en) 2004-12-02
EP1420827A1 (en) 2004-05-26
IL159714A (en) 2010-12-30
RU2322256C2 (ru) 2008-04-20
HUP0401441A2 (hu) 2004-12-28
PL210258B1 (pl) 2011-12-30
DE60233803D1 (de) 2009-11-05
US20060217313A1 (en) 2006-09-28
WO2003015822A1 (en) 2003-02-27
JP2005501852A (ja) 2005-01-20
BR0211932A (pt) 2004-10-26
CO5560586A2 (es) 2005-09-30
KR20040030120A (ko) 2004-04-08
CA2453646C (en) 2008-09-30
JP2009242410A (ja) 2009-10-22
SI1420827T1 (sl) 2010-01-29
ATE443527T1 (de) 2009-10-15
RU2004107899A (ru) 2005-05-10
EP1420827B8 (en) 2009-12-23
IL159714A0 (en) 2004-06-20
NZ531018A (en) 2006-03-31
CN1543357A (zh) 2004-11-03
BRPI0211932B1 (pt) 2016-12-06
EP1420827B1 (en) 2009-09-23
JP4959917B2 (ja) 2012-06-27
ES2333587T3 (es) 2010-02-24
CN1279981C (zh) 2006-10-18
PL365388A1 (en) 2005-01-10
DK1420827T3 (da) 2009-12-21
NO328069B1 (no) 2009-11-23
AU2002333443B2 (en) 2006-06-29
HUP0401441A3 (en) 2012-09-28
US9272040B2 (en) 2016-03-01
ECSP044961A (es) 2004-03-23

Similar Documents

Publication Publication Date Title
CY1109661T1 (el) 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
ATE401874T1 (de) Verabreichung von capsaicinoiden
MXPA05002814A (es) Formulacion para agentes lipofilicos.
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
EP2301531A3 (en) Combinations and modes of administration of therapeutic agents and combination therapy
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
BRPI0309665B8 (pt) método para analisar uma preparação de alfagalactosidase a
HK1113971A1 (en) Oral formulations for delivery of catecholic butanes including ndga compounds
CY1109013T1 (el) Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
PT1185253E (pt) Forma de administracao oral para administracao de uma combinacao fixa de tramadol e diclofenac
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
EA200501166A1 (ru) Составы и способы лечения тромбоцитемии
CY1108413T1 (el) Ενεσιμη φαρμακευτικη συνθεση που περιλαμβανει αιθανολη για την αγωγη των δισκοπαθειων
WO2000061141A3 (en) Methods and compositions for enhancing delivery of therapeutic agents to tissues
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
DE60019947D1 (de) Vorbeugung von kolorektalkrebs
HUP0500642A2 (hu) Csökkentett toxicitású ciszplatin készítmények és eljárás alkalmazásukra
AU2002319223A1 (en) Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
SE0203817D0 (sv) New composition
BR0312283A (pt) Combinação compreendendo um agente de alquilação e um agente redutor da atividade de vegf